中国中医药信息杂志
中國中醫藥信息雜誌
중국중의약신식잡지
CHINESE JOURNAL OF INFORMATION ON TRADITIONAL CHINESE MEDICINE
2014年
8期
23-26
,共4页
刘如秀%徐利亚%刘金凤%童建霞%陈靖
劉如秀%徐利亞%劉金鳳%童建霞%陳靖
류여수%서리아%류금봉%동건하%진정
冠心病%心绞痛%滋肾通阳活血方%白细胞介素-6%血清同型半胱氨酸%高敏C反应蛋白
冠心病%心絞痛%滋腎通暘活血方%白細胞介素-6%血清同型半胱氨痠%高敏C反應蛋白
관심병%심교통%자신통양활혈방%백세포개소-6%혈청동형반광안산%고민C반응단백
coronary heart disease%angina pectoris%Zishen Tongyang Huoxue Formula%interleukin-6%homocysteine%high sensitivity-C reactive protein
目的：观察滋肾通阳活血方联合西药治疗冠心病心绞痛临床疗效。方法将90例患者随机分为对照组、中药组、联合组各30例。对照组予常规西药治疗,中药组予滋肾通阳活血方治疗,联合组予滋肾通阳活血方联合常规西药治疗。3组疗程均为4周。观察治疗前后3组患者临床症状、心绞痛发作情况、心电图及血清生物标记物变化情况。结果3组均可明显改善中医临床症状,缩短心绞痛持续时间,减少硝酸甘油用量,联合组疗效优于其他2组(P＜0.05),中药组与对照组比较差异无统计学意义(P＞0.05)。对照组、中药组、联合组临床总有效率分别为83.33%(25/30)、83.33%(25/30)、96.67%(29/30),联合组疗效优于其他2组(P＜0.05)；心电图总有效率分别为70.00%(21/30)、76.67%(23/30)、76.67%(23/30),3组比较差异无统计学意义(P＞0.05)。治疗后,3组血清高敏C反应蛋白、白细胞介素-6和血清同型半胱氨酸水平均较治疗前降低(P＜0.05),联合组降低程度更明显(P＜0.05),中药组与对照组比较差异无统计学意义(P＞0.05)。3组患者治疗后血常规及肝、肾功能均无异常变化(P＞0.05)。结论滋肾通阳活血方联合常规西药治疗冠心病心绞痛疗效显著,安全可靠。
目的：觀察滋腎通暘活血方聯閤西藥治療冠心病心絞痛臨床療效。方法將90例患者隨機分為對照組、中藥組、聯閤組各30例。對照組予常規西藥治療,中藥組予滋腎通暘活血方治療,聯閤組予滋腎通暘活血方聯閤常規西藥治療。3組療程均為4週。觀察治療前後3組患者臨床癥狀、心絞痛髮作情況、心電圖及血清生物標記物變化情況。結果3組均可明顯改善中醫臨床癥狀,縮短心絞痛持續時間,減少硝痠甘油用量,聯閤組療效優于其他2組(P＜0.05),中藥組與對照組比較差異無統計學意義(P＞0.05)。對照組、中藥組、聯閤組臨床總有效率分彆為83.33%(25/30)、83.33%(25/30)、96.67%(29/30),聯閤組療效優于其他2組(P＜0.05)；心電圖總有效率分彆為70.00%(21/30)、76.67%(23/30)、76.67%(23/30),3組比較差異無統計學意義(P＞0.05)。治療後,3組血清高敏C反應蛋白、白細胞介素-6和血清同型半胱氨痠水平均較治療前降低(P＜0.05),聯閤組降低程度更明顯(P＜0.05),中藥組與對照組比較差異無統計學意義(P＞0.05)。3組患者治療後血常規及肝、腎功能均無異常變化(P＞0.05)。結論滋腎通暘活血方聯閤常規西藥治療冠心病心絞痛療效顯著,安全可靠。
목적：관찰자신통양활혈방연합서약치료관심병심교통림상료효。방법장90례환자수궤분위대조조、중약조、연합조각30례。대조조여상규서약치료,중약조여자신통양활혈방치료,연합조여자신통양활혈방연합상규서약치료。3조료정균위4주。관찰치료전후3조환자림상증상、심교통발작정황、심전도급혈청생물표기물변화정황。결과3조균가명현개선중의림상증상,축단심교통지속시간,감소초산감유용량,연합조료효우우기타2조(P＜0.05),중약조여대조조비교차이무통계학의의(P＞0.05)。대조조、중약조、연합조림상총유효솔분별위83.33%(25/30)、83.33%(25/30)、96.67%(29/30),연합조료효우우기타2조(P＜0.05)；심전도총유효솔분별위70.00%(21/30)、76.67%(23/30)、76.67%(23/30),3조비교차이무통계학의의(P＞0.05)。치료후,3조혈청고민C반응단백、백세포개소-6화혈청동형반광안산수평균교치료전강저(P＜0.05),연합조강저정도경명현(P＜0.05),중약조여대조조비교차이무통계학의의(P＞0.05)。3조환자치료후혈상규급간、신공능균무이상변화(P＞0.05)。결론자신통양활혈방연합상규서약치료관심병심교통료효현저,안전가고。
Objective To observe the clinical efficacy of Zishen Tongyang Huoxue Formula combined with western medicine in treating angina pectoris caused by coronary heart disease (CHD).Methods Ninety patients were randomly divided into control group, TCM group and combining group, each group of 30 cases. The control group was given western medicine standardized treatment;the TCM group was treated with Zishen Tongyang Huoxue Formula only;the combining group took Zishen Tongyang Huoxue Formula and western medicine standardized treatment. The treatment course for the three groups lasted for four weeks. The clinical presentations, angina pectoris, ECG and serum biomarkers of patients in the three groups were assessed and evaluated before and after treatment.Results The clinical symptoms of TCM were significantly improved;the duration of angina was shortened;the dosage of nitroglycerin reduced after the treatment (P<0.05). The effects in the combining group was more evident compared with the other two groups (P<0.05), but there was no statistical difference between the other two groups (P>0.05). The total TCM effective rates of three groups were 83.33% (25/30), 83.33% (25/30) and 96.67% (29/30), respectively, among which the combining group was more significant (P<0.05). The total ECG effective rates of three groups were 70.00% (21/30), 76.67% (23/30) and 76.67% (23/30), respectively. Hs-CRP, IL-6 and HCY in the three groups decreased after the treatment (P<0.05). The combining group was more significant than the other two groups (P<0.05), but there was no statistical difference between the other two groups (P>0.05). Blood routine test and hepatorenal function of the three groups were all in normal range before and after treatment (P>0.05).Conclusion Using Zishen Tongyang Huoxue Formula combined with western medicinein to treat angina pectoris is effective, safe, and reliable.
